Urinary exosomal MicroRNAs in incipient diabetic nephropathy

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Barutta, Federica ^a   Tricarico, Marinella ^a   Corbelli, Alessandro ^b,c   Annaratone, Laura ^d   Pinach, Silvia ^a   Grimaldi, Serena ^a   Bruno, Graziella ^a   Cimino, Daniela ^d   Taverna, Daniela ^d   Deregibus, Maria Chiara ^a   Rastaldi, Maria Pia ^b   Perin, Paolo Cavallo ^a   Gruden, Gabriella ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; MICRORNA; MICRORNA 130A; MICRORNA 145; MICRORNA 155; MICRORNA 424; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EXOSOME; FEMALE; GLOMERULUS; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MESANGIUM CELL; MICROALBUMINURIA; MOUSE; NONHUMAN; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; URINARY EXOSOME;

ALBUMINURIA; ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; EXOSOMES; GENE EXPRESSION; GLUCOSE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; MIDDLE AGED; UP-REGULATION;

EID: 84892387470     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073798     Document Type: Article

References (39)

1. Stevens LA, Greene T, Levey AS (2006) Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol 1: 874-884. doi:10.2215/CJN.00600206. PubMed: 17699300.
2. Lambers Heerspink HJ, de Zeeuw D (2010) Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 31: 458-461. doi:10.1159/000292501. PubMed: 20413960.
3. Glassock RJ (2010) Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 31: 462-465. doi:10.1159/000313553. PubMed: 20413961.
4. Wang G, Szeto CC (2007) Quantification of gene expression in urinary sediment for the study of renal diseases. Nephrology (Carlton) 12: 494-499. doi:10.1111/j.1440-1797.2007.00836.x.
5. van Balkom BW, Pisitkun T, Verhaar MC, Knepper MA (2011) Exosomes and the kidney: prospects for diagnosis and therapy of renal diseases. Kidney Int 80: 1138-1145. doi:10.1038/ki.2011.292. PubMed: 21881557.
6. Ludwig AK, Giebel B (2012) Exosomes: small vesicles participating in intercellular communication. Int J Biochem Cell Biol 44: 11-15. doi: 10.1016/j.biocel.2011.10.005. PubMed: 22024155.
7. He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531. doi:10.1038/nrg1379. PubMed: 15211354.
8. Shantikumar S, Caporali A, Emanueli C (2012) Role of miRNA in diabetes and its cardiovascular complications. Cardiovasc Res 93: 583-593. doi:10.1093/cvr/cvr300. PubMed: 22065734.
9. Kantharidis P, Wang B, Carew RM, Lan HY (2011) Diabetes complications: the miRNA perspective. Diabetes 60: 1832-1837. doi: 10.2337/db11-0082. PubMed: 21709278.
10. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK et al. (2008) Circulating miRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10513-10518. doi:10.1073/pnas.0804549105. PubMed: 18663219.
11. Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J et al. (2009) Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLOS ONE 4: e5532. doi:10.1371/journal.pone.0005532. PubMed: 19440243.
12. Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N et al. (2009) Plasma miRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 55: 1977-1983. doi:10.1373/clinchem.2009.131797. PubMed: 19745058.
13. Mangili R, Deferrari G, Mario U, Giampietro O, Navalesi R et al. (1992) Prevalence of hypertension and microalbuminuria in adult type 1 (insulin-dependent) diabetic patients without renal failure in Italy. 1. Validation of screening techniques to detect microalbuminuria. Acta Diabetol 29: 156-166. doi:10.1007/BF00573481.
14. Pisitkun T, Shen RF, Knepper MA (2004) Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A 101: 13368-13373. doi:10.1073/pnas.0403453101. PubMed: 15326289.
15. Tarabra E, Giunti S, Barutta F, Salvidio G, Burt D et al. (2009) Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes 58: 2109-2118. doi:10.2337/db08-0895. PubMed: 19587356.
16. Takemoto M, Asker N, Gerhardt H, Lundkvist A, Johansson BR et al. (2002) (20029 A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 161: 799-805. doi:10.1016/S0002-9440(10)64239-3. PubMed: 12213707.
17. Giunti S, Tesch GH, Pinach S, Burt DJ, Cooper ME et al. (2008) Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia 5: 198-207.
18. Simpson RJ, Lim JW, Moritz RL, Mathivanan S (2009). Expert. Rev Proteomics 6: 267-283. doi:10.1586/epr.09.17. PubMed: 19489699.
19. Rangrez AY, Massy ZA, Metzinger-Le Meuth V, Metzinger L (2011) miR-143 and miR-145: molecular keys to switch the phenotype of vascular smooth muscle cells. Circ Cardiovasc Genet 4: 197-205. doi: 10.1161/CIRCGENETICS.110.958702. PubMed: 21505201.
20. Harvey SJ, Jarad G, Cunningham J, Goldberg S, Schermer B et al. (2008) Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J Am Soc Nephrol 19: 2150-2158. doi: 10.1681/ASN.2008020233. PubMed: 18776121.
21. Denby L, Ramdas V, McBride MW, Wang J, Robinson H et al. (2011) miR-21 and miR-214 are consistently modulated during renal injury in rodent models. Am J Pathol 179: 661-672. doi:10.1016/j.ajpath. 2011.04.021. PubMed: 21704009.
22. Argyropoulos C, Wang K, McClarty S, Huang D, Bernardo J et al. (2013) Urinary microRNA profiling in the nephropathy of type 1 diabetes. PLOS ONE 8: e54662. doi:10.1371/journal.pone.0054662. PubMed: 23358711.
23. Kato M, Zhang J, Wang M, Lanting L, Yuan H et al. (2007) MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U-S-A 104: 3432-3437. doi:10.1073/pnas.0611192104. PubMed: 17360662.
24. Krupa A, Jenkins R, Luo DD, Lewis A, Phillips A et al. (2010) Loss of MicroRNA-192 Promotes Fibrogenesis in Diabetic Nephropathy. J Am Soc Nephrol 21: 438-447. doi:10.1681/ASN.2009050530. PubMed: 20056746.
25. Kato M, Park JT, Natarajan R (2012) MicroRNAs and the glomerulus. Exp Cell Res 318: 993-1000. doi:10.1016/j.yexcr.2012.02.034. PubMed: 22421514.
26. Natarajan R, Putta S, Kato M (2012) MicroRNAs and diabetic complications. J Cardiovasc Transl Res 5: 413-422.
27. Lu MC, Lai NS, Chen HC, Yu HC, Huang KY et al. (2013) Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis. Clin Exp Immunol 171: 91-99. doi:10.1111/j.1365-2249.2012.04676.x. PubMed: 23199328.
28. Yevdokimova N, Wahab NA, Mason RM (2001) Thrombospondin-1 is the key activator of TGF-b1 in human mesangial cells exposed to high glucose. J Am Soc Nephrol 12: 703-712. PubMed: 11274231.
29. Long X, Miano JM (2011) Transforming growth factor-beta1 (TGF-beta1) utilizes distinct pathways for the transcriptional activation of microRNA 143/145 in human coronary artery smooth muscle cells. J Biol Chem 286: 30119-30129. doi:10.1074/jbc.M111.258814. PubMed: 21712382.
30. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU et al. (2009) miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 460: 705-710. PubMed: 19578358.
31. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S et al. (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29: 341-345. doi:10.1038/nbt.1807. PubMed: 21423189.
32. El Andaloussi S, Lakhal S, Mäger I, Wood MJ (2012) Exosomes for targeted siRNA delivery across biological barriers. Adv Drug Deliv Rev; [Epub ahead of print]. PubMed: 22921840.
33. Record M, Subra C, Silvente-Poirot S, Poirot M (2011) Exosomes as intercellular signalosomes and pharmacological effectors. Biochem Pharmacol 81: 1171-1182. doi:10.1016/j.bcp.2011.02.011. PubMed: 21371441.
34. Fang DY, King HW, Li JY, Gleadle JM (2013) Exosomes and the kidney: blaming the messenger. Nephrology (Carlton) 18: 1-10. doi: 10.1111/nep.12005. PubMed: 23113949.
35. Martin MM, Lee EJ, Buckenberger JA, Schmittgen TD, Elton TS (2006) MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem 281: 18277-18284. doi:10.1074/jbc.M601496200. PubMed: 16675453.
36. Martin MM, Buckenberger JA, Jiang J, Malana GE, Nuovo GJ et al. (2007) The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microrna-155 binding. J Biol Chem 282: 24262-24269. doi:10.1074/jbc.M701050200. PubMed: 17588946.
37. Louafi F, Martinez-Nunez RT, Sanchez-Elsner T (2010) MicroRNA-155 targets SMAD2 and modulates the response of macrophages to transforming growth factor-beta. J Biol Chem 285: 41328-41336. doi: 10.1074/jbc.M110.146852. PubMed: 21036908.
38. Rai D, Kim SW, McKeller MR, Dahia PL, Aguiar RC (2010) Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci U S A 107: 3111-3116. doi: 10.1073/pnas.0910667107. PubMed: 20133617.
39. Chamorro-Jorganes A, Araldi E, Penalva LO, Sandhu D, Fernández- Hernando C et al. (2011) MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1. Arterioscler Thromb Vasc Biol 31: 2595-2606. doi: 10.1161/ATVBAHA.111.236521. PubMed: 21885851.